NDA 017812 · Hikma
Lithium Carbonate
Lithium Carbonate · Oral
Last checked: Nov 20, 2026Latest source record: Oct 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1980
Nov 26, 1980
Approved uses
1
Original approval plus efficacy supplements
Registered trials
246
60 Phase 3, 15 recruiting
FAERS reports
16,493
13,263 serious, 1,210 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LITHIUM TOXICITY Lithium toxicity is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations. Facilities for prompt and accurate serum lithium determinations should be available before initiating treatment [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.1 )] . WARNING: LITHIUM TOXICITY See full prescribing information for complete boxed warning. Lithium toxicity is closely related to serum lithium concentrations, and can occur at doses close to therapeutic concentrations. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy ( 2.3 , 5.1 ).
What it is approved for
From the label in effect Oct 16, 2026.
Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older [see Clinical Studies ( 14 )] Maintenance treatment in patients 7 years and older [see Clinical Studies ( 14 )] Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older ( 1 ) Maintenance treatment in patients 7 years and older ( 1 )
Mechanism: The mechanism of action of lithium as a mood stabilizing agent is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 26, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
- LITHIUM CARBONATE · LITHIUM CARBONATE 150MG · CAPSULE, ORAL · Prescription · TE AB
- LITHIUM CARBONATE · LITHIUM CARBONATE 600MG · CAPSULE, ORAL · Prescription · TE AB
- LITHIUM CARBONATE · LITHIUM CARBONATE 300MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lithium Carbonate" as an intervention, any sponsor and status, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- A Study of Aripiprazole (Abilify) in Patients With Bipolar ManiaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00261443 · 1,270 participants · Start Sep 2005 · Primary completion Jun 2009
Drug: Lithium or Valproate with placebo (PBO); Lithium or Valproate with Aripiprazole · For: Bipolar Disorder
Sites: Tuscaloosa, Alabama; Anaheim, California; Cerritos, California · 83 sites in all
- Quetiapine Fumarate Bipolar Maintenance MonotherapyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00314184 · 1,255 participants · Start Mar 2005
Drug: quetiapine fumarate · For: Bipolar Disorder
Sites: Cerritos, California; San Diego, California; Santa Ana, California · 95 sites in all
- Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or DivalproexPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01358357 · 965 participants · Start Jun 2011 · Primary completion Apr 2015
Drug: Lurasidone; Placebo · For: Bipolar I Disorder
Sites: Dothan, Alabama; Glendale, California; Los Angeles, California · 105 sites in all
- The Early Medication Change (EMC) TrialPivotal-lookingCompleted
K. LiebAcademic, hospital or other
NCT00974155 · 889 participants · Start Sep 2009 · Primary completion May 2014
Drug: Escitalopram, venlafaxine, lithium; Escitalopram, venlafaxine · For: Depression
Sites: Mainz, Germany
- Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological CharacteristicsPivotal-lookingStatus unknown
Shanghai Mental Health CenterAcademic, hospital or other
NCT03219008 · 800 participants (planned) · Start Aug 1, 2017 · Primary completion Dec 2019
Drug: Fluoxetine; fluoxetine + Amfebutamone and 4 more · For: Depressive Disorder
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxicity to various agents1,246
- drug ineffective1,124
- tremor1,066
- drug interaction999
- nausea811
- weight increased794
- insomnia698
- depression693
- fatigue671
- vomiting663
- confusional state636
- somnolence627
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 530 |
| 2005 | 452 |
| 2006 | 746 |
| 2007 | 1,023 |
| 2008 | 723 |
| 2009 | 826 |
| 2010 | 798 |
| 2011 | 1,114 |
| 2012 | 1,406 |
| 2013 | 499 |
| 2014 | 398 |
| 2015 | 615 |
| 2016 | 694 |
| 2017 | 584 |
| 2018 | 717 |
| 2019 | 677 |
| 2020 | 687 |
| 2021 | 762 |
| 2022 | 740 |
| 2023 | 723 |
| 2024 | 654 |
| 2025 | 594 |
| 2026 | 531 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lithium Carbonate (Lithium Carbonate)
2024 spending
$7.1M
Beneficiaries
101,068
724,316 claims
Per beneficiary
$71
$0.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,937,834 |
| 2021 | $7,501,144 |
| 2022 | $7,074,281 |
| 2023 | $7,437,848 |
| 2024 | $7,127,156 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cognitive therapy vs medications in the treatment of moderate to severe depression.
DeRubeis RJ, Hollon SD, Amsterdam JD, et al. · Arch Gen Psychiatry 2005 · Clinical Trial, Comparative Study
- Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial.
Devanand DP, Crocco E, Forester BP, et al. · Am J Geriatr Psychiatry 2022 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Hemodialysis for lithium poisoning.
Lavonas EJ, Buchanan J · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
- Lithium therapy in patients on dialysis: A systematic review.
McGrane IR, Omar FA, Morgan NF, et al. · Int J Psychiatry Med 2022 · Systematic Review
- Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial.
Gildengers AG, Ibrahim TS, Anderson SJ, et al. · JAMA Neurol 2026 · Randomized Controlled Trial
- Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.
van Eijk RPA, Jones AR, Sproviero W, et al. · Neurology 2017 · Meta-Analysis, Review
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.